We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Telik has reported positive interim data from a multicenter Phase I/IIa clinical
study evaluating Telcyta (TLK286) in combination with cisplatin in the first-line
treatment of advanced non-small cell lung cancer.
Cell Genesys has reported additional results from its second multicenter Phase
II trial of GVAX vaccine for prostate cancer which evaluated escalating doses
of the vaccine in 80 patients with advanced hormone-refractory metastatic prostate
cancer.
Threshold Pharmaceuticals has announced follow-up results of a Phase II study of its investigational drug candidate, TH-070 (lonidamine) for the treatment of benign prostatic hyperplasia (BPH).
Results from two Phase III, placebo-controlled clinical trials found that approximately
two-thirds of patients with moderate-to-severe, active ulcerative colitis (UC)
treated with Remicade demonstrated a significant improvement in symptoms.
Join FDAnews Tuesday, May 24, for a 90-minute audioconference on "Reduce
Supply Chain Risks: How the FDA Expects You to Manage Outsourced Suppliers."
Learn how to navigate the unexpected liabilities and meet your legal and regulatory
responsibilities from a former top FDA investigator, Martin Browning,
now president of EduQuest. On May 25, join FDAnews for "FDA's New Risk
Management Guidances: Roadmaps and RiskMAPs for Improving Drug Safety,"
presented by Greg Levine, partner with Arnold & Porter's pharmaceutical
and medical device practice. Discover how to apply FDA-endorsed risk-management
tactics and RiskMAPs to each stage of your product's lifecycle.
Neurologix, which through its subsidiary Neurologix Research, is engaged in
the R&D of proprietary treatments for disorders of the brain and central
nervous system (CNS) primarily using gene therapies, has licensed the humanin
gene from Keio University in Tokyo as part of a strategic move to broaden its
product portfolio.
Human Genome Sciences has announced the results of a preclinical study comparing
the antiviral efficacy of unmodified interferon alpha with three longer-acting
modified forms of interferon alpha, including Albuferon.
Kosan Biosciences has presented preclinical data describing the properties of
novel erythromycin-based motilin agonists, motilides, for stimulating gastrointestinal
motility.
CuraGen has reported the final Phase I results for a single-dose of velafermin
(CG53135) for the prevention of oral mucositis (OM) in patients receiving high-dose
chemotherapy followed by autologous hematopoietic stem cell transplantation.